Bisphosphonates in the treatment of metabolic bone diseases
- PMID: 20485910
- DOI: 10.1590/s0004-27302010000200017
Bisphosphonates in the treatment of metabolic bone diseases
Abstract
Osteoporosis is a disease characterized by low bone mass associated with the deterioration of microarchitecture, due to an imbalance either in high bone resorption or low bone formation or in both, leading to a high risk of fractures. Bisphosphonates are medications which reduce the ability of osteoclasts to induce bone resorption and consequently improve the balance between resorption and formation. There are bisphosphonates approved for the prevention and treatment of osteoporosis. Administration can be oral (daily, weekly or monthly) or intravenous (quarterly or yearly). These medications are well tolerated and with the correct instructions of administration have a good safety profile. Serious side effects, such as, osteonecrosis of jaw is very rare. Bisphosphonates are the most prescribed medication for the treatment of osteoporosis.
Similar articles
-
[Inflammation of the jaws during treatment with bisphosphonates].Dtsch Med Wochenschr. 2011 Oct;136(41):2109-10. doi: 10.1055/s-0031-1292022. Epub 2011 Oct 4. Dtsch Med Wochenschr. 2011. PMID: 21971888 German. No abstract available.
-
Safety considerations with bisphosphonates for the treatment of osteoporosis.Drug Saf. 2007;30(9):755-63. doi: 10.2165/00002018-200730090-00003. Drug Saf. 2007. PMID: 17722968 Review.
-
[Bisphosphonates in osteoporosis therapy. Standards and perspectives].Orthopade. 2007 Feb;36(2):110-7. doi: 10.1007/s00132-006-1035-6. Orthopade. 2007. PMID: 17252258 Review. German.
-
Bisphosphonates and metabolic bone disease in the ICU.Curr Opin Clin Nutr Metab Care. 2009 Mar;12(2):190-5. doi: 10.1097/mco.0b013e328321cda6. Curr Opin Clin Nutr Metab Care. 2009. PMID: 19209471 Review.
-
Bisphosphonates and osteonecrosis: potential treatment or serious complication?Orthop Clin North Am. 2009 Apr;40(2):223-34. doi: 10.1016/j.ocl.2008.12.002. Orthop Clin North Am. 2009. PMID: 19358907 Review.
Cited by
-
Toward a Mathematical Modeling of Diseases' Impact on Bone Remodeling: Technical Review.Front Bioeng Biotechnol. 2020 Nov 2;8:584198. doi: 10.3389/fbioe.2020.584198. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33224935 Free PMC article. Review.
-
A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosis.J Appl Oral Sci. 2011 Aug;19(4):293-300. doi: 10.1590/s1678-77572011000400001. J Appl Oral Sci. 2011. PMID: 21952925 Free PMC article.
-
Tumour macrophages as potential targets of bisphosphonates.J Transl Med. 2011 Oct 17;9:177. doi: 10.1186/1479-5876-9-177. J Transl Med. 2011. PMID: 22005011 Free PMC article. Review.
-
Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta.J Bone Miner Res. 2019 Nov;34(11):2061-2074. doi: 10.1002/jbmr.3831. Epub 2019 Oct 9. J Bone Miner Res. 2019. PMID: 31310351 Free PMC article.
-
Astaxanthin as a Potent Antioxidant for Promoting Bone Health: An Up-to-Date Review.Antioxidants (Basel). 2023 Jul 24;12(7):1480. doi: 10.3390/antiox12071480. Antioxidants (Basel). 2023. PMID: 37508018 Free PMC article. Review.